{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T09:18:43Z","timestamp":1724404723996},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s12098-009-0216-9","type":"journal-article","created":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T05:28:58Z","timestamp":1257917338000},"page":"1017-1021","source":"Crossref","is-referenced-by-count":13,"title":["Lipodystrophy and metabolic complications of highly active antiretroviral therapy"],"prefix":"10.1007","volume":"76","author":[{"given":"Ankit","family":"Parakh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand Prakash","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshu","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,12]]},"reference":[{"key":"216_CR1","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A. Carr","year":"1999","unstructured":"Carr A, Samaras K, Thorsidottir A, Kaufman GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999, 353:2093\u20132099.","journal-title":"Lancet"},{"key":"216_CR2","first-page":"383","volume":"25","author":"C. Vigouroux","year":"1999","unstructured":"Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabet Metab 1999, 25:383\u2013392.","journal-title":"Diabet Metab"},{"key":"216_CR3","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/00002030-199912240-00002","volume":"13","author":"S. Safrin","year":"1999","unstructured":"Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493\u20132505.","journal-title":"AIDS"},{"key":"216_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/135965350100600102","volume":"6","author":"M. John","year":"2001","unstructured":"John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9\u201320.","journal-title":"Antivir Ther"},{"key":"216_CR5","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1210\/jc.2002-020794","volume":"87","author":"D.S. Chen","year":"2002","unstructured":"Chen DS, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87: 4845\u20134856.","journal-title":"J Clin Endocrinol Metab"},{"key":"216_CR6","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jc.2002-021704","volume":"88","author":"M.K. Leow","year":"2003","unstructured":"Leow MK, Addy CL, Mantzoros CS. Clinical review 159. Human immunodeficiency virus\/highly active antiretroviral therapy associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003; 88: 1961\u20131976.","journal-title":"J Clin Endocrinol Metab"},{"key":"216_CR7","first-page":"199","volume":"39","author":"S.N. Pujari","year":"2005","unstructured":"Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organizationrecommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005; 39: 199\u2013202.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"216_CR8","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1086\/392516","volume":"38","author":"S. Saghayam","year":"2004","unstructured":"Saghayam S, Chaguturu SK, Kumarasamy N, Solomon S, Mayer KH, Wanke C. Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in southern India. Clin Infect Dis 2004; 38: 1646\u20131647.","journal-title":"Clin Infect Dis"},{"key":"216_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00006454-200205000-00011","volume":"21","author":"R.A. Amaya","year":"2002","unstructured":"Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405\u2013410.","journal-title":"Pediatr Infect Dis J"},{"key":"216_CR10","first-page":"463","volume":"22","author":"J.L. Bockhorst","year":"2003","unstructured":"Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, Allen HF. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 2003; 22: 463\u2013465.","journal-title":"Pediatr Infect Dis J"},{"key":"216_CR11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.aids.0000131334.38172.01","volume":"18","author":"European Paediatric Lipodystrophy Group.","year":"2004","unstructured":"European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIVinfected children in Europe. AIDS 2004; 18: 1443\u20131451.","journal-title":"AIDS"},{"key":"216_CR12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00431-004-1610-y","volume":"164","author":"A.M. S\u00e1nchez Torres","year":"2005","unstructured":"S\u00e1nchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garc\u00eda-Miguel MJ, De Jos\u00e9 G\u00f3mez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005; 164: 271\u2013276.","journal-title":"Eur J Pediatr"},{"key":"216_CR13","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1542\/peds.114.2.e235","volume":"114","author":"P. Taylor","year":"2004","unstructured":"Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitorcontaining, highly active antiretroviral therapy regimens. Pediatrics 2004; 114: e235\u2013e242.","journal-title":"Pediatrics"},{"key":"216_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00431-006-0193-1","volume":"166","author":"L. Ene","year":"2007","unstructured":"Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007; 166: 13\u201321.","journal-title":"Eur J Pediatr"},{"key":"216_CR15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.inf.0000215003.32256.aa","volume":"25","author":"K. Hartman","year":"2006","unstructured":"Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 427\u2013431.","journal-title":"Pediatr Infect Dis J"},{"key":"216_CR16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4158\/EP.12.5.514","volume":"12","author":"B. Ergun-Longmire","year":"2006","unstructured":"Ergun-Longmire B, Lin-Su K, Dunn AM, Chan L, Ham K, Sison C et al. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract 2006; 12: 514\u2013521.","journal-title":"Endocr Pract"},{"key":"216_CR17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.qai.0000218344.88304.db","volume":"41","author":"R.J. Carter","year":"2006","unstructured":"Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P et al. Perinatal AIDS Collaborative Transmission Study-HIV Follow-up after Perinatal Exposure (PACTS-HOPE) Group. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999\u20132004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41: 453\u2013460.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"216_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.arcmed.2005.05.013","volume":"37","author":"F. Sol\u00f3rzano Santos","year":"2006","unstructured":"Sol\u00f3rzano Santos F, Gochicoa Rangel LG, Palacios Saucedo G, V\u00e1zquez Rosales G, Miranda Novales MG. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res 2006; 37: 129\u2013132.","journal-title":"Arch Med Res"},{"key":"216_CR19","first-page":"956","volume":"88","author":"K. Lapphra","year":"2005","unstructured":"Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai 2005; 88: 956\u2013966.","journal-title":"J Med Assoc Thai"},{"key":"216_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.qai.0000178930.93033.f2","volume":"40","author":"M. Beregszaszi","year":"2005","unstructured":"Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIVinfected children. J Acquir Immune Defic Syndr 2005; 40: 161\u2013168.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"216_CR21","volume-title":"Scaling up Antiretroviral Therapy in Resourcelimited Settings: Treatment Guidelines for a Public Health Approach","author":"World Health Organization.","year":"2003","unstructured":"World Health Organization. Scaling up Antiretroviral Therapy in Resourcelimited Settings: Treatment Guidelines for a Public Health Approach. Geneva: World Health Organization; 2003."},{"key":"216_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/adc.45.239.13","volume":"45","author":"W.A. Marshall","year":"1970","unstructured":"Marshall WA, Tanner JM. Variations in pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13\u201323.","journal-title":"Arch Dis Child"},{"key":"216_CR23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","volume":"361","author":"A. Carr","year":"2003","unstructured":"Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIVinfected adults: a case-control study. Lancet 2003; 361:726\u2013735.","journal-title":"Lancet"},{"key":"216_CR24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00126334-200308150-00004","volume":"33","author":"A. Carr","year":"2003","unstructured":"Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003; 33:571\u2013576.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"216_CR25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1542\/peds.89.3.509","volume":"89","author":"R. Lauer","year":"1992","unstructured":"Lauer R, Barness LA, Clark R. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992; 89: 525\u2013584.","journal-title":"Pediatrics"},{"key":"216_CR26","unstructured":"Divisions of AIDS, National Institute of Allergy and Infectious Diseases. Toxicity table for grading severity of pediatric adverse experiences. April 1994. Available at: http:\/\/www.hptn.org\/Web%20Documents\/Regulatory_Resources ."}],"container-title":["The Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-009-0216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12098-009-0216-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-009-0216-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T13:58:27Z","timestamp":1685195907000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12098-009-0216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1007\/s12098-009-0216-9","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}